Global science and technology leader Thermo Fisher Scientific has announced a significant expansion. This targets its Research and Development (R&D) Centre of Excellence in Bengaluru. This substantial investment aims to advance antibody research India and manufacturing capabilities. Consequently, the ₹160 crore expansion underscores India’s growing role in global life sciences innovation.
Key Details of the Bengaluru R&D Expansion
The newly expanded facility spans 37,000 sq. ft. It features advanced automation and analytical platforms. This state-of-the-art center will primarily concentrate on antibody design, development, and manufacturing. Furthermore, the company anticipates generating over 100 new employment opportunities within Karnataka in the upcoming years. The inauguration event saw prominent figures in attendance. For instance, Sanjeev Kumar Gupta, CEO of Karnataka Digital Economy Mission (KDEM), participated. This highlights the strategic importance of this development.
Government and Industry Perspectives on Antibody Research India
Priyank Kharge, Karnataka’s Minister for Electronics, IT & Bt, commended the expansion. He stated that this move reinforces Karnataka’s position as a premier hub for biotechnology and life sciences. Through the Karnataka Biotechnology Mission and supportive state policies, the government actively fosters innovation. It also develops talent and facilitates collaboration across government, academia, and industry. Moreover, Mr. Kharge emphasized that Thermo Fisher’s investment significantly strengthens Karnataka’s ability. It allows the state to contribute to India’s broader biotechnology vision. Gianluca Pettiti, Executive Vice President at Thermo Fisher Scientific, also affirmed the company’s commitment to India’s innovation ecosystem. He specifically noted Bengaluru’s strategic importance.
Thermo Fisher’s Impact and Future Vision
For the past 18 years, Thermo Fisher’s Bengaluru Centre of Excellence has made remarkable contributions. It has successfully developed more than 2,000 recombinant antibodies. These are pivotal for research in areas such as infectious diseases, antiviral studies, and cancer biology. Its comprehensive antibody validation program has rigorously tested over 25,000 antibodies. In addition, the manufacturing division has produced more than 2,000 primary and secondary antibodies for global researchers. Manoj Prasad, Vice President, IT & Digital Solutions, APAC & MEA, Thermo Fisher Scientific, added that this expansion will accelerate product innovation. It will also enhance the company’s global R&D network. This robust infrastructure and influx of talent will undoubtedly speed up discovery. It will also support customers in biotech, diagnostics, and academia.
Karnataka’s Flourishing Biotechnology Ecosystem
Karnataka stands as a powerhouse in India’s life sciences sector. The state contributes over 10% of India’s pharmaceutical revenues. It also generates nearly 60% of its biotechnology revenues. Its bioeconomy boasts a valuation of approximately USD 31 billion. Furthermore, Karnataka houses 221 formulation units, 74 bulk drug units, and 35 contract research organizations (CROs). This expansion by Thermo Fisher aligns perfectly with Karnataka’s Global Capability Center (GCC) ambitions. It further cements the state’s reputation as a leading destination for high-value, research-driven operations. These operations integrate discovery, design, and manufacturing.
Frequently Asked Questions
Q1: What is the purpose of Thermo Fisher’s investment in Bengaluru?
Thermo Fisher Scientific is investing ₹160 crore to expand its R&D Centre of Excellence in Bengaluru. This expansion aims to advance innovation in antibody research and manufacturing, supporting scientific progress in India and globally.
Q2: How many new jobs will this expansion create?
The 37,000 sq. ft. expansion is expected to create over 100 new jobs in Karnataka in the coming years, primarily focusing on antibody design, development, and manufacturing roles.
Q3: What role does Karnataka play in India’s biotechnology sector?
Karnataka is a significant contributor to India’s biotechnology and pharmaceutical sectors. It accounts for nearly 60% of India’s biotechnology revenues and over 10% of its pharmaceutical revenues, with a bioeconomy valued at around USD 31 billion. The state is a hub for research and advanced manufacturing.
References
- Thermo Fisher invests ₹160 crore to expand Bengaluru R&D facility, to create 100jobs – ETHealthworld
- Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
- Thermo Fisher Scientific invests Rs 160 Cr to advance innovation in antibody research and manufacturing – IndiaMedToday
- Thermo Fisher Enhances India’s Biotechnology Landscape with R&D Expansion | Science-Environment – Devdiscourse
- Thermo Fisher Scientific invests Rs. 160 crore, Bengaluru R&D will create over 100 jobs
- Thermo Fisher Scientific inaugurates expanded R&D centre of excellence in Bengaluru
- Karnataka: Leading India’s Biotech Boom with Innovation and Investment – eGov Magazine
- Karnataka eyes tripling bioeconomy to $100 bn by 2030 with new biotechnology policy
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.